InvestorsHub Logo

TheDane

09/19/14 9:00 AM

#70007 RE: cabel #70004

Maybe he said something else in the R&R talk...this is what I could find...

Aug 19 PR..."The company expects data from the trial to be available in the fourth quarter of 2014."

http://finance.yahoo.com/news/cellceutix-completes-enrollment-phase-2b-123000703.html


Sept. 9 PR..."Cellceutix will not know the actual cure rates per treatment arm until the data is unblinded in October/November. However, the Company is very optimistic and views the high average cure rate on the blinded data as a very good sign for Brilacidin. Assuming positive results after unblinding, Cellceutix will have proven that Brilacidin is a safe and effective drug in the Phase 2 trial, and all activities will be triggered for initiation of a pivotal Phase 3 trial."

http://finance.yahoo.com/news/cellceutix-provides-initial-observations-completed-190000867.html